Elekta AB (publ) (EKTA-B.ST)
SEK 61.7
(2.32%)
SEK 61.7
(2.32%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 3.41 SEK | 38.06% |
| 2022 | 2.47 SEK | -18.21% |
| 2021 | 3.02 SEK | -7.93% |
| 2020 | 3.28 SEK | 15.49% |
| 2019 | 2.84 SEK | -9.55% |
| 2018 | 3.14 SEK | 9.03% |
| 2017 | 2.88 SEK | 772.73% |
| 2016 | 0.33 SEK | -8.33% |
| 2015 | 0.36 SEK | -75.17% |
| 2014 | 1.45 SEK | -51.83% |
| 2013 | 3.01 SEK | -14.49% |
| 2012 | 3.52 SEK | 7.98% |
| 2011 | 3.26 SEK | 18.12% |
| 2010 | 2.76 SEK | 21.59% |
| 2009 | 2.27 SEK | 51.33% |
| 2008 | 1.50 SEK | 33.93% |
| 2007 | 1.12 SEK | 20.43% |
| 2006 | 0.93 SEK | 14.81% |
| 2005 | 0.81 SEK | 26.56% |
| 2004 | 0.64 SEK | 0.0% |
| 2003 | 0.64 SEK | 4.92% |
| 2002 | 0.61 SEK | 56.41% |
| 2001 | 0.39 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.18 SEK | -83.49% |
| 2023 Q1 | 0.62 SEK | -56.64% |
| 2023 Q2 | 0.90 SEK | 45.16% |
| 2023 Q3 | 0.80 SEK | -11.11% |
| 2023 Q4 | 1.09 SEK | 36.25% |
| 2023 FY | - SEK | 38.06% |
| 2022 Q2 | 0.32 SEK | 100.0% |
| 2022 Q3 | 0.57 SEK | 78.12% |
| 2022 FY | - SEK | -18.21% |
| 2022 Q4 | 1.43 SEK | 150.88% |
| 2022 Q1 | 0.16 SEK | -85.32% |
| 2021 Q3 | 0.60 SEK | -40.0% |
| 2021 Q4 | 1.09 SEK | 81.67% |
| 2021 Q2 | 1.00 SEK | 203.03% |
| 2021 Q1 | 0.33 SEK | -62.92% |
| 2021 FY | - SEK | -7.93% |
| 2020 Q3 | 0.84 SEK | -14.29% |
| 2020 FY | - SEK | 15.49% |
| 2020 Q1 | 0.57 SEK | -46.73% |
| 2020 Q2 | 0.98 SEK | 71.93% |
| 2020 Q4 | 0.89 SEK | 5.95% |
| 2019 FY | - SEK | -9.55% |
| 2019 Q1 | 0.38 SEK | -72.86% |
| 2019 Q2 | 0.58 SEK | 52.63% |
| 2019 Q3 | 0.81 SEK | 39.66% |
| 2019 Q4 | 1.07 SEK | 32.1% |
| 2018 FY | - SEK | 9.03% |
| 2018 Q4 | 1.40 SEK | 154.55% |
| 2018 Q3 | 0.55 SEK | -26.67% |
| 2018 Q2 | 0.75 SEK | 74.42% |
| 2018 Q1 | 0.43 SEK | -69.72% |
| 2017 Q4 | 1.42 SEK | 57.78% |
| 2017 Q3 | 0.90 SEK | 12.5% |
| 2017 Q2 | 0.80 SEK | 30869.23% |
| 2017 Q1 | -0.00 SEK | -101.08% |
| 2017 FY | - SEK | 772.73% |
| 2016 Q1 | -0.17 SEK | -189.47% |
| 2016 Q2 | 0.14 SEK | 182.35% |
| 2016 Q3 | 0.11 SEK | -21.43% |
| 2016 Q4 | 0.24 SEK | 118.18% |
| 2016 FY | - SEK | -8.33% |
| 2015 Q1 | -0.34 SEK | -138.2% |
| 2015 Q4 | 0.19 SEK | 1800.0% |
| 2015 Q3 | 0.01 SEK | -97.96% |
| 2015 Q2 | 0.49 SEK | 244.12% |
| 2015 FY | - SEK | -75.17% |
| 2014 Q4 | 0.89 SEK | 128.21% |
| 2014 FY | - SEK | -51.83% |
| 2014 Q3 | 0.39 SEK | -25.0% |
| 2014 Q2 | 0.52 SEK | 244.44% |
| 2014 Q1 | -0.36 SEK | -116.59% |
| 2013 Q4 | 2.17 SEK | 456.41% |
| 2013 FY | - SEK | -14.49% |
| 2013 Q1 | -0.02 SEK | -100.7% |
| 2013 Q2 | 0.49 SEK | 3221.02% |
| 2013 Q3 | 0.39 SEK | -20.41% |
| 2012 Q2 | 0.67 SEK | 2133.33% |
| 2012 Q3 | 0.61 SEK | -8.96% |
| 2012 Q4 | 2.24 SEK | 267.21% |
| 2012 FY | - SEK | 7.98% |
| 2012 Q1 | 0.03 SEK | -97.95% |
| 2011 Q3 | 1.05 SEK | 59.09% |
| 2011 Q4 | 1.46 SEK | 39.05% |
| 2011 FY | - SEK | 18.12% |
| 2011 Q1 | 0.13 SEK | -90.85% |
| 2011 Q2 | 0.66 SEK | 407.69% |
| 2010 Q1 | 0.28 SEK | -78.13% |
| 2010 Q4 | 1.42 SEK | 173.08% |
| 2010 FY | - SEK | 21.59% |
| 2010 Q3 | 0.52 SEK | -3.7% |
| 2010 Q2 | 0.54 SEK | 92.86% |
| 2009 Q1 | 0.16 SEK | 0.0% |
| 2009 Q3 | 0.40 SEK | -6.98% |
| 2009 Q2 | 0.43 SEK | 168.75% |
| 2009 Q4 | 1.28 SEK | 220.0% |
| 2009 FY | - SEK | 51.33% |
| 2008 FY | - SEK | 33.93% |
| 2007 FY | - SEK | 20.43% |
| 2006 FY | - SEK | 14.81% |
| 2005 FY | - SEK | 26.56% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 4.92% |
| 2002 FY | - SEK | 56.41% |
| 2001 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AddLife AB (publ) | 1.56 SEK | -118.59% |
| Biotage AB (publ) | 3.33 SEK | -2.402% |
| Bonesupport Holding AB (publ) | 3.77 SEK | 9.549% |
| Doxa AB (publ) | 0.60 SEK | -468.333% |
| iZafe Group AB (publ) | -0.14 SEK | 2535.714% |
| Ortivus AB (publ) | -0.41 SEK | 931.707% |
| Ortivus AB (publ) | -0.41 SEK | 931.707% |
| Q-linea AB (publ) | -3.48 SEK | 197.989% |
| S2Medical AB (publ) | -0.14 SEK | 2535.714% |
| Synsam AB (publ) | 2.09 SEK | -63.158% |